Pateclizumab

Pateclizumab is a monoclonal antibody that was designed for the treatment of rheumatoid arthritis. It was developed by Genentech, a biotechnology company based in the United States. Pateclizumab targets the interleukin 6 (IL-6) pathway, which plays a crucial role in the inflammatory response that characterizes rheumatoid arthritis.

Mechanism of Action

Pateclizumab works by binding to the interleukin 6 receptor (IL-6R), thereby inhibiting the interaction between IL-6 and its receptor. This prevents the activation of the IL-6 pathway, which is known to contribute to the inflammation and joint damage seen in rheumatoid arthritis.

Clinical Trials

Pateclizumab has undergone Phase II clinical trials for the treatment of rheumatoid arthritis. The results of these trials showed that pateclizumab was well-tolerated and led to improvements in disease activity scores in patients with rheumatoid arthritis.

See Also

• Monoclonal antibodies
• Rheumatoid arthritis
• Interleukin 6
• Genentech

References

Pateclizumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski